PJ002

Indication: Type 2 Diabetes Mellitus (T2DM)

This product is a GLP-1 analogue withdaily administration frequency,which can reduce blood glucose in diabetic patients intelligently without causing hypoglycemia and protect β-cells.This product designed by the unique series expression of the TE-Pep platform to obtain the manufacturing process of high-quality and low-cost products. At present,phase I clinical trials have been completed.

PJ001

Indication: Diabetes Mellitus (DM)

This product is the third generation of insulin, which has the advantages of better blood glucose control, lower risk of hypoglycemia and more flexible injection time compared with the previous two generation products. Subcutaneous administration once a day can greatly improve the deficiency of frequent administration of insulin products and improve the compliance of patients.This product is independently developed through thedesign ofthe unique signal peptide and short C-peptide structure, high throughput screening expression system to obtain the manufacturing process characterized by highyield, highquality, and short cycle.The project has entered phase I clinical trials.

PJ012

Glucagon is also known as anti-insulin.It is a hormone, along with insulin, secreted by islet cells in the pancreas of vertebrates.It works against insulin to increase blood glucose.PEG-BIO adopts TE-Pep technology to achieve the production and evaluation of API in kilogram grade, quality of which is consistent with that of the original drug.New injection formulations and non-injection delivery methodsare beingdeveloped. 

PJ007

Indication: Type 2 Diabetes Mellitus (T2DM)；Obesity

This product is a long-acting GLP-1 analogue with weekly subcutaneous administration frequency. Its efficacy on reducing HbA1c and weight in type 2 diabetes patients is dose-dependent, which is more effective and better toleratedcompared with Liraglutide listed for many years. PEG-BIO completeda cost-effective,high-quality original research about API through TE-Pep platform technologyand self-developed process route.This biosimilar injection dosage forms is underway of pharmacology and toxicology evaluation, and oral dosage form are also in research.

PJ009

Indication: Short Bowel Syndrome (SBS)

Glucagon like peptide-2 (GLP-2) is apeptide compoundsecretedbyintestinal epidermal cellstimulated by nutrients. GLP-2 analogues have multiple biological effects, clinicallyused for short bowel syndrome.This product proposed to administrateonce daily by subcutaneous injection.PEG-BIO adopted the technique of TE-Pep and self-developed process route to finish research of materials and preparations.In addition, the long-acting products are under development, which can be used to treat short bowel syndrome and inflammatory bowel disease caused by Chemoradiotherapy-InducedDiarrhea (CID).